Jump to main content
Jump to site search

Issue 11, 2018
Previous Article Next Article

Arsenic trioxide preferentially binds to the ring finger protein PML: understanding target selection of the drug

Author affiliations

Abstract

Arsenic trioxide (ATO) is used in the clinic for the treatment of acute promyelocytic leukemia by targeting the protein PML. However, many zinc-finger proteins could also be reactive to arsenic in cells. Here we found that ATO preferentially binds to the ring-finger domain of PML in a protein mixture with zinc-finger domains. These results provide the molecular basis of the target selection of ATO in cells.

Graphical abstract: Arsenic trioxide preferentially binds to the ring finger protein PML: understanding target selection of the drug

Back to tab navigation

Supplementary files

Publication details

The article was received on 25 Jul 2018, accepted on 18 Sep 2018 and first published on 19 Sep 2018


Article type: Communication
DOI: 10.1039/C8MT00202A
Citation: Metallomics, 2018,10, 1564-1569
  •   Request permissions

    Arsenic trioxide preferentially binds to the ring finger protein PML: understanding target selection of the drug

    C. Kaiming, Y. Sheng, S. Zheng, S. Yuan, G. Huang and Y. Liu, Metallomics, 2018, 10, 1564
    DOI: 10.1039/C8MT00202A

Search articles by author

Spotlight

Advertisements